Scilex Holding (SCLXW) Retained Earnings (2020 - 2026)
Scilex Holding (SCLXW) recorded quarterly Retained Earnings of -$965.1 million in Q1 2026, down 4.69% quarter-over-quarter from -$921.8 million in Q4 2025, and down 63.81% on a YoY basis from -$2.7 billion in Q1 2025.
Scilex Holding (SCLXW) Retained Earnings (2020 - 2026) Analysis & Trends
Scilex Holding's Retained Earnings history runs 7 years deep, the most recent figure standing at -$965.1 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 63.81% year-over-year to -$965.1 million; the TTM figure through Mar 2026 stood at -$965.1 million (down 63.81% YoY), while the FY2025 annual figure was -$921.8 million, down 63.71% from the prior year.
- Retained Earnings was -$965.1 million for Q1 2026 at Scilex Holding, down from -$921.8 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $5.0 million in Q3 2024 to a low of -$965.1 million in Q1 2026.
- Historically, Retained Earnings has averaged -$368.3 million across 5 years, with a median of -$420.0 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings soared 101.07% in 2024, then plunged 34213.45% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$375.9 million in 2022, then dropped by 24.71% to -$468.8 million in 2023, then decreased by 20.1% to -$563.1 million in 2024, then tumbled by 63.71% to -$921.8 million in 2025, then decreased by 4.69% to -$965.1 million in 2026.
- The last three Retained Earnings figures came in at -$965.1 million (Q1 2026), -$921.8 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 1.90 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 29.51 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | -14.83 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -17.87 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 66.72 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -190.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 78.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -7.20 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -1.37 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn | -965.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -965.06 Mn |
| Dec 31, 2025 | -921.79 Mn |
| Sep 30, 2025 | 3.35 Mn |
| Jun 30, 2025 | -631.44 Mn |
| Mar 31, 2025 | -589.13 Mn |
| Dec 31, 2024 | -563.05 Mn |
| Sep 30, 2024 | 5.01 Mn |
| Jun 30, 2024 | 1.85 Mn |
| Mar 31, 2024 | -514.62 Mn |
| Sep 30, 2023 | -468.80 Mn |
| Jun 30, 2023 | -433.30 Mn |
| Mar 31, 2023 | -406.70 Mn |
| Dec 31, 2022 | -375.91 Mn |
| Sep 30, 2022 | -12.00 Mn |
| Jun 30, 2022 | -10.77 Mn |
| Mar 31, 2022 | -10.54 Mn |
| Dec 31, 2021 | -352.55 Mn |
| Sep 30, 2021 | -9.83 Mn |
| Jun 30, 2021 | -8.39 Mn |
| Mar 31, 2021 | 1.32 Mn |